BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05935332 (RPT193 in Moderate to Severe T2-high Asthma): BVCT ex-ante prediction vs. reported outcome

On 10 Aug 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 9 May 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05935332
Drug Name
RPT193
Drug MoA
oral CCR4 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Respiratory Tract Diseases
Indication
Moderate to Severe T2-high Asthma
Human Patients
38
Sponsor
RAPT Therapeutics
Phase
Phase 2

Prediction of , index 1213

Prospective Prediction
Prediction Index
1213
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
273 days in advance
Readout Data Interpretation
terminated due to clinical holds.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 in Adults With Moderate-to-severe T2-high Asthma Who Are Partially Controlled on Inhaled Corticosteroid and Long-acting Beta 2 Agonist Therapy
Phase
Phase 2
Status
Terminated
Enrollment
38
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Conditions
Asthma
Interventions
DRUG: RPT193; OTHER: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-07-05
Primary completion
2024-06-21
Completion
2024-06-21
Results first posted
2026-03-23
Primary outcomes
  • Proportion of Participants With a Loss of Asthma Control Event as Defined by Criteria Listed (14 weeks)

NCT05935332 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials